TY-9591 for EGFR-mutant lung cancer spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and under 80 years old.
- Your lung cancer is NSCLC with confirmed brain metastases.
- Your tumor has an EGFR “sensitive” mutation (like exon 19 deletion or L858R).
- You haven’t had anti-cancer treatment for advanced/metastatic lung cancer before, and you haven’t had an EGFR medicine before.
- Your brain metastases are stable, and you have at least one measurable tumor spot on scans.
- You’re well enough to participate (tests show adequate liver/kidney/blood health, and your heart rhythm and lung history don’t create major risk).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
This trial tests a new targeted drug (TY-9591) combined with chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has a specific EGFR mutation. It may offer a more effective option for those who haven't had prior therapy.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This trial tests a new drug called SYS6010 combined with osimertinib for people with advanced non-small cell lung cancer that has specific EGFR mutations. It aims to see if this combination works better than current treatments.
This trial tests a treatment for people with advanced non-small cell lung cancer that has spread to the brain or spine. It is for those whose cancer has a specific EGFR mutation (19Del or L858R) and who have not yet received treatment for their advanced cancer.
This trial tests adding a brain-sparing radiation technique to the targeted therapy drug osimertinib for people with EGFR-mutant lung adenocarcinoma that has spread to the brain and is causing symptoms. The goal is to see if this combination can better control the brain tumors while protecting the hippocampus, a key memory area.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.